Volume : 10, Issue : 05, May – 2023
Title:
71.REVIEW OF GASTRO RETENTIVE DRUG DELIVERY SYSTEMS EFFECTIVE AGAINST H PYLORI
Authors :
Dr. Sandip R. Pawar, Miss. Utkarsha Khachane, Dr. Bharat V. Jain, Mr. Rohit S. Patil, Mr. Yogesh A. Chaudhari
Abstract :
Oral drug delivery still remains user friendly form, having the highest degree of patient compliance, and highly preferred route of drug administration. As such, drug for chronic condition are often administered orally for ease of long term use. The peroral dosage form cannot achieve prolongation of effective plasma concentration and effective bioavailability due to the changing environment in the GIT. This is because of various physiological problems like gastric emptying, motility, pH of the stomach etc. This can be overcome by developing suitable dosage form that could be retained in the stomach for prolong period. Drugs having narrow absorption window, stability problem and which need to act locally in stomach can be formulated as a floating drug delivery system. Such systems improve bioavailability, enhances absorption despite first pass effect, avoid the fluctuation in plasma drug concentration and maintain desirable level by continuous drug release. It also improves patient compliance by reducing dosing frequency and decrease wastage of drug. The multiple particulate unit dosage forms are more reliable and are freely distributed throughout GI tracts as compared to single unit formulation, which suffers “all or none concept.
Keywords: Gastro Retentive, H Pylori, Stomach
Cite This Article:
Please cite this article in press Sandip R. Pawar et al, Review Of Gastro Retentive Drug Delivery Systems Effective Against H Pylori., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
References:
1. Hoogerwerf HA, Pasricha PJ. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease; Goodman &Gilman‟s pharmacological basis of therapeutics Brunton LL, Lazo JS, Parker KL, editors. USA: McGraw- Hill Companies, Inc, 2006; 11: 967-981.
2. Abbreviated Drug Class Review: Proton Pump Inhibitors, VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Homepage on the internet, 2006; 05. Available from: http://www.pbm.va.gov/reviews/ppiabbreviatedrev iew.pdf
3. Hogan J. Modified release coatings, Pharmaceutical Coating Technology, Graham Cole,editor. UK: Taylor & Francis Ltd, 1995; 428.
4. Tian L, Zhang Y; Tang X, Sustained-Release Pellets Prepared by Combination of Wax Matrices and Double-Layer Coatings for Extremely Water-Soluble Drugs, Drug Development and Industrial Pharmacy. June, 2008; 34(6): 569 – 576.
5. Tanberk, New galenic process for the omeprazole pellets‟, EP0519144.Claudio N,Influence of formulation and process parameter on pellets production by powder layering technique using aqueous solution‟, AAPSPharm Scitech, 2014; 1(2).
6. Sharma D, Sharma A. Gastroretentive drug delivey system- A mini review. Asian Pac.J. Health Sci, 2014; 1(2): 80-89.
7. Kumar S, Jamil F, Rajput M and Sharma S. Gastro Retentive drug delivery system: features and facts. International journal of research in pharmaceutical and biomedical sciences, 2012; 3(1): 125-135.
8. Mentis A, Lehours P, Megraud F. Epidemiology and Diagnosis of Helicobacter pylori infection. Helicobacter, 2015; 20(1): 1–7.
9. Chey WD, Wong BC, Practice Parameters Committee of the American College of G.American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol, 2007; 102: 1808–1825. pmid:17608775
10. Atkinson NS, Braden B. Helicobacter Pylori Infection: Diagnostic Strategies in Primary Diagnosis and After Therapy. Dig Dis Sci, 2016; 61: 19–24. pmid:26391269.
11. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of elicobacter pylori Infection. Am J Gastroenterol, 2017; 112: 212.
12. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter, 2005; 10: 157.
13. Chawla G, Gupta P, Koradia V and Bansal AK. Gastroretension: A means to address regional variability in intestinal drug absorption. Pharmaceutical Technology. 2003;27:50-68.
14. Garg Re and Gupta GD. Progress in controlled gastro retentive delivery systems. Topical Journal of Pharmaceutical Research. 2008;7(3):1055-1066.
15. Yadav M, Sharma P, Chaudhary V and Srivastava B. Gastro retentive drug delivery system: a promising approach. Indo American Journal of Pharmaceutical Research. 2016;6(4):5225-5235.
16. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC and Falson Fir. Gastro retentive dosage forms: Overview and special case of Helicobacter pylori. J Control Release. 2006;111( 1-2):1 -18.
17. Patil JM, Hirlekar RS, Gide PS and Kadam VJ. Trends in floating drug delivery systems. Journal of Scientific and Industrial Research. 2006;65(1):11-21.
18. Fujimori J, Machida Y, Tanaka S and Nagai T. Effect of magnetically controlled gastric residence of sustained release tablets on bioavailability of acetaminophen. International Journal of Pharmaceutics. 1995;119: 47-55.
19. Klausner EA, Lavy E, Friedman M and Hoffmann A. Expandable gastroretentive dosage forms. Journal of Controlled drug Release. 2003;90:143-162.
20. Thapa P and Jeong S. effects of formulation and process variables on gastroretentive floating tablets with a high- dose soluble drug and experimental design approach. Pharmaceutics. 2018;10:1-25.